These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29889676)

  • 21. Rivaroxaban (Xarelto) - a new peripheral artery disease indication.
    Med Lett Drugs Ther; 2021 Nov; 63(1636):172-173. PubMed ID: 35085206
    [No Abstract]   [Full Text] [Related]  

  • 22. Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study.
    Yasaka M; Minematsu K; Toyoda K; Yamagami H; Yoshimura S; Nagao T; Mori E; Hirano T; Hamasaki T; Yamaguchi T
    J Stroke Cerebrovasc Dis; 2016 Jun; 25(6):1342-8. PubMed ID: 26987488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bipolar disorder, ischemic stroke, mitral valve vegetation and recurrent venous thrombosis due to antiphospholipid syndrome despite rivaroxaban.
    Rokos J; Heger M; Stöllberger C; Finsterer J; Laufer G; Wiedemann D
    Int J Cardiol; 2016 Oct; 221():383-4. PubMed ID: 27404710
    [No Abstract]   [Full Text] [Related]  

  • 24. Open Repair of a Ruptured Abdominal Aortic Aneurysm on a Patient Under Rivaroxaban and Clopidogrel.
    Poulou A; Alexiou E; Geroulakos G; Lazaris AM
    Ann Vasc Surg; 2019 Jul; 58():379.e5-379.e8. PubMed ID: 30684617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events.
    Med Lett Drugs Ther; 2018 Dec; 60(1561):196-197. PubMed ID: 30653475
    [No Abstract]   [Full Text] [Related]  

  • 26. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
    Kreutz R; Persson PB; Kubitza D; Thelen K; Heitmeier S; Schwers S; Becka M; Hemmrich M
    J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects.
    Moore KT; Byra W; Vaidyanathan S; Natarajan J; Ariyawansa J; Salih H; Turner KC
    Br J Clin Pharmacol; 2015 Jun; 79(6):907-17. PubMed ID: 25475601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience.
    Arachchillage D; Reynolds R; Devey T; Maclean R; Kitchen S; van Veen JJ
    Thromb Res; 2016 Nov; 147():32-35. PubMed ID: 27669125
    [No Abstract]   [Full Text] [Related]  

  • 29. [Rivaroxaban as monotherapy in patients with venous thromboembolism].
    Krivoshchekov EP; Migunov IA; Romanov VE
    Khirurgiia (Mosk); 2016; (10):61-65. PubMed ID: 27804937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A RCT study of Rivaroxaban, low-molecular-weight heparin, and sequential medication regimens for the prevention of venous thrombosis after internal fixation of hip fracture.
    Tang Y; Wang K; Shi Z; Yang P; Dang X
    Biomed Pharmacother; 2017 Aug; 92():982-988. PubMed ID: 28605879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism.
    Kabuki T; Nakanishi R; Hisatake S; Fujii T; Dobashi S; Wakakura S; Kiuchi S; Fujino T; Ikeda T
    J Cardiol; 2017 Aug; 70(2):163-168. PubMed ID: 27979674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice.
    Vimalesvaran K; Dockrill SJ; Gorog DA
    Vasc Health Risk Manag; 2018; 14():13-21. PubMed ID: 29391805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
    JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intracardiac Thrombus Following Rivaroxaban Treatment in a Patient with Atrial Fibrillation Associated with Rheumatic Heart Disease.
    Ohara H; Yamamoto S; Nagano K; Hashikawa K
    J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104325. PubMed ID: 31427189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.
    Siegmund HU; Burghaus R; Kubitza D; Coboeken K
    Br J Clin Pharmacol; 2015 Jun; 79(6):959-66. PubMed ID: 25510952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The COMPASS study].
    Calabrò P; Gragnano F; Visconti LO
    G Ital Cardiol (Rome); 2018 Jan; 19(1):1-7. PubMed ID: 29451504
    [No Abstract]   [Full Text] [Related]  

  • 37. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
    Weitz JI; Lensing AWA; Prins MH; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Decousus H; Freitas MCS; Holberg G; Kakkar AK; Haskell L; van Bellen B; Pap AF; Berkowitz SD; Verhamme P; Wells PS; Prandoni P;
    N Engl J Med; 2017 Mar; 376(13):1211-1222. PubMed ID: 28316279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study.
    Haas S; Holberg G; Kreutz R; Lassen MR; Mantovani L; Haupt V; Vogtländer K; Turpie AG
    Vasc Health Risk Manag; 2016; 12():209-18. PubMed ID: 27274266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of rivaroxaban anticoagulation by nonactivated prothrombin complex concentrate in urgent surgery.
    Chic Acevedo C; Velasco F; Herrera C
    Future Cardiol; 2015 Sep; 11(5):525-9. PubMed ID: 26090568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of livedoid vasculopathy recurrence by prolonged administration of rivaroxaban.
    Drerup C; Goerge T
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e532. PubMed ID: 28609556
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.